Table 3.
Association between the prevalence of skin diseases and the duration of T2DM who developed from NGT/IGT and T2DM groups.
| Skin diseases, n (%) | |||||||
| Categories | T2DM patients (n) | Development from groups | Average duration (years), mean (SE) | Normal | Patients | χ 2 | P |
| Disturbances of pigmentation | 175 | NGT/IGT | 16.37 (9.58) | 115 (65.7) | 60 (34.3) | 11.64 | <0.01 |
| 89 | T2DM | 30.00 (0.00) | 39 (43.8) | 50 (56.2) | |||
| Allergic dermatoses | 175 | NGT/IGT | 16.37 (9.58) | 155 (88.6) | 20 (11.4) | 0.11 | 0.75 |
| 89 | T2DM | 30.00 (0.00) | 80 (89.9) | 9 (10.1) | |||
| Diseases of the skin appendages | 175 | NGT/IGT | 16.37 (9.58) | 159 (90.9) | 16 (9.1) | 1.80 | 0.18 |
| 89 | T2DM | 30.00 (0.00) | 76 (85.4) | 13 (14.6) | |||
| Skin tumors | 175 | NGT/IGT | 16.37 (9.58) | 131 (74.9) | 44 (25.1) | 0.79 | 0.37 |
| 89 | T2DM | 30.00 (0.00) | 71 (79.8) | 18 (20.2) | |||
| Neurological and psychogenic dermatoses | 175 | NGT/IGT | 16.37 (9.58) | 138 (78.9) | 37 (21.1) | 4.92 | 0.03 |
| 89 | T2DM | 30.00 (0.00) | 59 (66.3) | 30 (33.7) | |||
| Infectious skin diseases | 175 | NGT/IGT | 16.37 (9.58) | 66 (37.7) | 109 (62.3) | 0.21 | 0.65 |
| 89 | T2DM | 30.00 (0.00) | 31 (34.8) | 58 (65.2) | |||
IGT: Impaired glucose tolerance; NGT: Normal glucose tolerance; SE: Standard error; T2DM: Type 2 diabetes mellitus.